Pneumococcal Vaccines: Can They Cut Antibiotic Use?

How can pneumococcal vaccines help reduce antibiotic resistance?

The CDC's review of antimicrobial resistance during COVID-19 describes how disrupted infection prevention, prolonged hospital stays and antibiotic exposure undermined earlier progress. Its February 2025 update explicitly identifies vaccines as part of the response. This is an established pandemic lesson rather than a newly announced October finding: preventing infections can protect patients while reducing demand for antimicrobial treatment. [CDC review](https://www.cdc.gov/antimicrobial-resistance/data-research/threats/covid-19.html)

Pneumococcal vaccination targets a bacterium responsible for pneumonia and serious invasive infections. WHO's 2024 modeling identifies expanded pneumococcal vaccination as one way to reduce antibiotic consumption. The mechanism is straightforward: fewer infections mean fewer occasions when treatment is needed, potentially reducing the selection pressure that favors resistant organisms. However, modeled reductions depend on vaccination coverage and other assumptions; they do not establish how many antibiotic prescriptions a particular vaccine will prevent in an individual patient. [WHO analysis](https://www.who.int/news/item/10-10-2024-better-use-of-vaccines-could-reduce-antibiotic-use-by-2.5-billion-doses-annually--says-who)

What does the clinical evidence show about Capvaxive?

Capvaxive, also called PCV21 and studied as V116, is a 21-valent pneumococcal conjugate vaccine initially approved in the United States in 2024. The randomized phase 3 STRIDE-3 trial compared V116 with PCV20 and evaluated safety, tolerability and immunogenicity—the ability to provoke an immune response. Such studies help assess whether a vaccine generates antibodies against the bacterial types it targets. They do not automatically establish a reduction in antibiotic prescriptions or resistant infections. [STRIDE-3 publication](https://pubmed.ncbi.nlm.nih.gov/38964361/)

The distinction matters for interpreting approval. Capvaxive's adult pneumonia indication received accelerated approval based on opsonophagocytic activity, a laboratory measure of antibody-assisted bacterial killing. Its prescribing information states that continued approval for this indication may depend on confirmation of clinical benefit. The vaccine also has an indication for preventing specified invasive pneumococcal infections. These regulatory indications support its use within vaccination guidance, but they should not be presented as a measured reduction in antimicrobial resistance. [FDA prescribing information](https://www.fda.gov/media/179426/download)

To establish an effect on antibiotic use, research would need to measure outcomes such as subsequent prescriptions, confirmed infections and hospital admissions. Antibody measurements and population models answer different questions; neither supplies a product-specific estimate of antibiotic courses avoided.

Which adults should discuss pneumococcal vaccination?

CDC guidance updated in February 2026 recommends PCV15, PCV20 or PCV21 for adults aged 50 or older who have never received a pneumococcal conjugate vaccine or whose history is unknown. Certain younger adults also qualify because of increased disease risk. Previous vaccination changes the schedule, so reviewing the actual vaccine record is more useful than assuming that every adult needs another dose. [CDC recommendations](https://www.cdc.gov/pneumococcal/hcp/vaccine-recommendations/index.html)

For adults starting vaccination under this recommendation, PCV20 or PCV21 completes the pneumococcal series without a subsequent PPSV23 dose. PCV15 generally requires PPSV23 afterward, with timing determined by clinical circumstances. Capvaxive is administered as a single 0.5 mL intramuscular injection. Its commonly reported adult reactions include injection-site pain, fatigue and headache; a history of severe allergy to a component or diphtheria toxoid is a contraindication. These choices concern prevention before illness occurs. [CDC vaccination schedules](https://www.cdc.gov/pneumococcal/hcp/vaccine-recommendations/index.html), [FDA prescribing information](https://www.fda.gov/media/179426/download)